
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): May 22, 2015

Carbylan Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36830
(Commission
File Number)

20-0915291
(I.R.S. Employer
Identification No.)

3181 Porter Drive, Palo Alto, California
(Address of principal executive offices)

94304
(Zip Code)

Registrant's telephone number, including area code: (650) 855-6777

Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 22, 2015, Michael White resigned from his position as Chief Financial Officer and Vice President, Finance of Carbylan Therapeutics, Inc. Mr. White's resignation did not result from any disagreement with, or inaccuracy or omission in, the Company's accounting systems or financial reporting. All functional areas reporting to Mr. White will report to David Renzi, Chief Executive Officer of the Company. In connection with Mr. White's resignation, the Company's compensation committee has provided Mr. White with the general severance benefits set forth in his employment agreement filed as an exhibit to the Company's Registration Statement on Form S-1 and has extended his option exercise period by sixty days.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 28, 2015

Carbylan Therapeutics, Inc.

By: /s/ David M. Renzi

David M. Renzi

President and Chief Executive Officer

-3-